BTG to commercialise sleep disorder sensor:
This article was originally published in Clinica
The international subsidiary of UK technology transfer company BTG is looking for a partner to commercialise a non-invasive monitor for respiratory disorders such as sleep apnoea and sudden infant death syndrome (SIDS). The monitor uses a fibre-optic coupler sensor which is placed on a person's pulse point. This allows a single sensor to detect heartbeat and respiration rate at the same time. A second sensor can be used to monitor blood pressure. To detect SIDS a single fibre-optic cable could be incorporated into a thin mattress, says BTG. Unlike most infant apnoea monitors, it would not need to be connected to the baby. Software associated with the sensor can identify changes in breathing while eliminating the effects of body movements.
You may also be interested in...
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.
Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.